Why ScanSource Stock Is Soaring Today

ScanSource shares were up 16.2% midday after fiscal Q4 sales rose ~17% to $953.1M, exceeding the $151M-above-consensus analyst target, and non-GAAP EPS came in at $1.46 vs. $0.32 above estimates. The company also announced a $220.5M acquisition of MicroAge, expected to close by Sept. 30 and to be accretive to sales, margins, adjusted earnings, and free cash flow in year one. Forward guidance calls for fiscal 2027 sales growth of 6%–10% (excluding MicroAge), adjusted EBITDA of $158M–$165M, and adjusted free cash flow of at least $85M.

Analysis

The cleanest read-through is not “earnings beat” but that the business is getting a short-cycle operating leverage reset: in a low-moat distribution model, a 100-200 bps improvement in mix, pricing, and inventory turns can disproportionately lift EBITDA and sentiment before it shows up in the street’s revenue model. That said, these names are notoriously mean-reverting; if this was partly channel replenishment or backlog catch-up, the next two quarters matter more than the beat itself. The market is likely to reward SCSC for proof of execution, but it should not yet be granted a higher multiple unless organic growth holds above mid-single digits without balance-sheet drift.

The MicroAge deal is the real second-order signal. If integration is smooth, the acquisition can deepen wallet share and improve bargaining power versus smaller regional resellers, which should pressure weaker private competitors first and force more discounting at the low end of the channel. The risk is that distribution M&A often looks accretive on paper while quietly consuming cash in working capital; the key tell will be whether free cash flow conversion stays intact as the deal closes and inventory normalizes.

From a trading standpoint, the move is probably stronger over days than months unless management validates the 2027 bridge with another quarter of organic acceleration. The contrarian risk is that consensus is extrapolating a cyclical pop into a structural inflection; if Q1/Q2 order rates soften or integration costs rise, the stock can give back a large share of the gap. A failure mode would be guidance reset below the current growth band or FCF materially under the implied run-rate after the acquisition closes.

Key Decisions for Investors

• Tactically long SCSC on any post-gap consolidation, with a 1-3 month horizon; thesis works only if organic revenue stays >5% and the deal closes on schedule by Sept. 30. Trim/review if the stock retraces more than half the gap and volume dries up.
• Pair trade: long SCSC / short SNX or ARW over the next 1-3 months to express relative execution and M&A optionality, not the sector beta. Falsify if SNX/ARW report stronger organic growth or better cash conversion next quarter.
• Do not chase strength above the opening gap unless the next earnings call confirms no deterioration in free cash flow conversion; this is a low-moat business where one quarter of good pricing can be mistaken for a durable re-rating.
• Watch MicroAge close and first post-close integration commentary as the main catalyst; if management flags customer retention issues, leverage creep, or working-capital pressure, treat the acquisition as a value trap rather than an accretive add-on.